Medpace (NASDAQ:MEDP) CEO Sells $2,106,035.10 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 3,510 shares of the business’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $600.01, for a total value of $2,106,035.10. Following the sale, the chief executive officer owned 638,946 shares in the company, valued at $383,373,989.46. This represents a 0.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Medpace Trading Up 2.5%

MEDP traded up $14.52 on Wednesday, reaching $585.49. The stock had a trading volume of 580,873 shares, compared to its average volume of 364,017. The company has a market capitalization of $16.34 billion, a price-to-earnings ratio of 34.32, a price-to-earnings-growth ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a 50-day moving average of $498.48 and a 200-day moving average of $493.41.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same period last year, the firm posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.55 EPS for the current fiscal year.

Institutional Trading of Medpace

Large investors have recently made changes to their positions in the company. NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the period. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Sivia Capital Partners LLC bought a new stake in Medpace during the 2nd quarter valued at $296,000. Finally, M&T Bank Corp increased its stake in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a research note on Thursday, July 23rd. Mizuho increased their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research report on Thursday, July 23rd. Truist Financial lifted their target price on Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Two analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.